University of Calgary

Calgary, Alberta, Canada

35 recruiting

Showing 120 of 116 trials

Recruiting
Phase 3

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Bronchiectasis
Boehringer Ingelheim1,755 enrolled470 locationsNCT06872892
Recruiting
Phase 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled444 locationsNCT06632457
Recruiting
Phase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled525 locationsNCT06632444
Recruiting
Not Applicable

The Fourth Left Atrial Appendage Occlusion Study

Atrial FibrillationStroke, IschemicSystemic Embolism
Hamilton Health Sciences Corporation4,000 enrolled140 locationsNCT05963698
Recruiting
Phase 3

Pridopidine Phase 3 Study in Huntington's Disease

Huntington Disease
Prilenia400 enrolledNCT07609108
Recruiting
Phase 3

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Primary Biliary Cholangitis
Gilead Sciences402 enrolled205 locationsNCT06051617
Recruiting
Phase 1Phase 2

Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

HemoglobinopathiesMetabolic DisordersHematologic, Immune, or Bone Marrow Disorders+1 more
Washington University School of Medicine220 enrolled28 locationsNCT00920972
Recruiting
Phase 2

Cannabis (THC vs. CBD) in Multiple Sclerosis

Multiple Sclerosis
University of Calgary30 enrolledNCT06261489
Recruiting

A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study

Mycobacterium Avium Complex Pulmonary Disease
Radboud University Medical Center100 enrolled11 locationsNCT05906316
Recruiting
Not Applicable

Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis

Scleroderma, SystemicDigital Ulcer
Primus Pharmaceuticals45 enrolled5 locationsNCT06256575
Recruiting
Phase 1

Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy

Persisting Symptoms After Concussion
University of Calgary40 enrolled1 locationNCT06615908
Recruiting
Phase 2

Subjective Experience Following Psilocybin

Investigating the Importance of the Subjective Psychedelic Experience
University of Calgary128 enrolled1 locationNCT06768944
Recruiting

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

Primary Biliary Cholangitis
Ipsen424 enrolled68 locationsNCT06447168
Recruiting

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

Ulcerative Colitis (UC)Crohn Disease (CD)Inflammatory Bowel Disease (IBD)+1 more
TIDHI Innovation Inc.200 enrolled12 locationsNCT07245394
Recruiting

Charactertizing Growth Hormone Deficiency in Traumatic Brain Injury

Traumatic Brain InjuryGrowth Hormone Deficiency
University of Calgary200 enrolledNCT07795736
Recruiting
Phase 3

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1
Novo Nordisk A/S877 enrolled196 locationsNCT07076199
Recruiting

International CRDS Registry

Calcium Release Deficiency Syndrome
Population Health Research Institute500 enrolled18 locationsNCT06508164
Recruiting
Phase 2

Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

Hepatitis B, Chronic
AusperBio Therapeutics Inc.70 enrolledNCT07654283
Recruiting
Phase 2

COgnitioN With VERiciGuat Evaluation in Heart Failure

Heart FailureCognitive Impairment
University of Alberta120 enrolled4 locationsNCT06601465
Recruiting
Phase 3

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled292 locationsNCT07207811